Theratechnologies (TSE:TH) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Theratechnologies Inc. has secured exclusive rights from Ionis Pharmaceuticals to commercialize two RNA-targeted investigational medicines, olezarsen and donidalorsen, in Canada. This agreement aims to expand Theratechnologies’ portfolio beyond HIV treatments by addressing unmet medical needs for conditions like familial chylomicronemia syndrome and hereditary angioedema. Both companies are committed to delivering innovative therapies in North America, with regulatory submissions to Health Canada expected in 2025.
For further insights into TSE:TH stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Can MicroStrategy Stock Reach Around $1,000? Here’s What This Investor Expects
- Bank of America Chimes in on Intel Stock, Warning of a Bumpy Road Ahead
- ‘Don’t Jump on the Bandwagon,’ Says J.P. Morgan About Super Micro Computer Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
